Saturday 17 October 2026
Export ADXN’s income statement to Excel — free account
Addex Therapeutics Ltd. Sponsored ADR
ADXN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 100.8%, EPS grew 25.7% and free cash flow fell 2.73%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.76
0.26
−8.61%
Follow ADXN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
38.74 | 68.53 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(12.61) | (10.13) | — | — | |
P/B ratio |
1.19 | 1.20 | — | — | |
Price to Tangible BV |
1.20 | 1.21 | — | — | |
EV/Sales |
26.82 | 48.91 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(3.31) | (1.88) | — | — | |
EV/FCF |
(3.30) | (1.88) | — | — | |
Quick Ratio |
1.91 | 1.38 | 0.79 | 0.58 | |
Current Ratio |
2.01 | 1.40 | 0.97 | 0.76 | |
Net Debt/EBITDA |
3.15 | 2.06 | 1.99 | 1.24 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.01 | 0.00 | 0.00 | |
Operating CF/Net income |
0.36 | 0.30 | 0.45 | 0.26 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(869.90) | 90.99 | (180.09) | (544.40) | |
Research and Development Expense of Revenue |
769.00% | (6,760.00%) | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,742.86% | (92,050.00%) | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
55.26% | (1,150.00%) | 0.00% | 0.00% | |
Graham Net Nets |
0.14 | 0.01 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(85.58%) | (120.76%) | — | — | |
Free Cash Flow Yield |
(20.99%) | (37.99%) | — | — | |
Revenue per Share |
0.04 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.75) | (0.76) | (0.99) | (0.57) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.75) | (0.76) | (0.99) | (0.57) | |
Cash per Share |
2.91 | 2.21 | 1.21 | 0.95 | |
Shareholders Equity per Share |
7.93 | 6.43 | 4.25 | 2.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.93 | 6.43 | 4.25 | 2.36 | |
Free Cash Flow |
(0.70) | (0.68) | (0.98) | (0.58) | |
Working Capital |
1.49 | 0.58 | (0.04) | (0.41) | |
Net Current Asset Value |
1.24 | 0.10 | (0.36) | (0.68) | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
0.31 | 0.02 | 0.04 | 0.04 | |
Average Payables |
1.24 | 1.17 | 1.23 | 1.49 | |
Average Assets |
11.61 | 9.91 | 8.31 | 7.36 | |
Average Common Equity |
10.11 | 8.37 | 6.71 | 5.58 |
Columns are period end dates · fundamentals updated 30 Sep 2026